로딩 중...
52주 최고가 대비 44.4% 위치
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
SEC 13F 공시 기준 · 2026-Q1
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|
| 주요 재무실적 (USD) | ||||
| 매출액 | $8.08B | $8.54B | $9.26B | $9.47B |
| 영업이익 | $2.93B | $3.07B | $3.39B | $3.60B |
| 당기순이익 | $2.11B | $2.34B | $2.49B | $2.67B |
| 잉여현금흐름 (FCF) | $1.33B | $1.62B | $2.30B | $2.28B |
| 수익성 비율 | ||||
| 영업이익률 | 36.2% | 35.9% | 36.6% | 38.0% |
| 순이익률 | 26.2% | 27.4% | 26.9% | 28.2% |
| ROE (자기자본이익률) | 48.0% | 46.9% | 52.1% | 80.2% |
| ROA (자산이익률) | 14.2% | 16.4% | 17.5% | 17.3% |
| 성장성 비율 | ||||
| 매출 성장률 (YoY) | - | 5.7% | 8.3% | 2.3% |
| EPS 성장률 (YoY) | - | 12.9% | 7.9% | 10.1% |
| 투자 지표 & 가치배수 | ||||
| PER (주가수익배수) | 35.4x | 35.9x | 30.6x | 20.6x |
| PBR (주가순자산배수) | 15.1x | 15.3x | 14.7x | 15.6x |
| PSR (주가매출배수) | 8.2x | 8.9x | 7.6x | 5.5x |
| FCF Yield | 2.0% | 2.1% | 3.3% | 4.4% |
| 재무 건전성 (안정성) | ||||
| 부채비율 (D/E) | 1.84 | 1.35 | 1.41 | 2.77 |
| 유동비율 | 2.37 | 3.36 | 1.75 | 3.03 |
MOLINA HEALTHCARE INC
$179.86
$9.4B